Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 3 1Phase 1/2 1

Status

Recruiting 7Active not recruiting 4Not yet recruiting 2

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Breast Neoplasms 79Carcinoma, Non-Small-Cell Lung 71Prostatic Neoplasms 68Neoplasms 52Multiple Myeloma 46Lung Neoplasms 42Colorectal Neoplasms 37Melanoma 32Lymphoma, Non-Hodgkin 30Pancreatic Neoplasms 29Neoplasm Metastasis 29Lymphoma 28Leukemia, Myeloid, Acute 27Squamous Cell Carcinoma of Head and Neck 26Ovarian Neoplasms 26Carcinoma, Renal Cell 25Precursor Cell Lymphoblastic Leukemia-Lymphoma 22Leukemia, Lymphocytic, Chronic, B-Cell 22Endometrial Neoplasms 22Stomach Neoplasms 20Sarcoma 20Carcinoma, Hepatocellular 20Urinary Bladder Neoplasms 19Glioma 19Uterine Cervical Neoplasms 18Recurrence 18Rectal Neoplasms 18Lymphoma, Mantle-Cell 17Hematologic Neoplasms 17Head and Neck Neoplasms 17

Interventions

radium Ra 223 dichloride 1olaparib 1Radium-223 1Pluvicto 1Nivolumab 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Active not recruiting × Metastatic Castration-resistant Prostate Cancer × 30 days × Clear all
NCT03732820 2026-06-02

Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer

AstraZeneca

Phase 3 Active not recruiting
895 enrolled 19 charts 1 FDA
Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT04109729 2026-06-01

Rad2Nivo

University of Utah

Phase 1 Active not recruiting
39 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT05682443 2026-05-22

PRESERVE-006

OncoC4, Inc.

Phase 1/2 Active not recruiting
148 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT06052306 2026-05-18

A Study to Learn How Safe the Study Treatment Actinium-225-macropa-pelgifatamab (BAY3546828) is, How it Affects the Body, How it Moves Into, Through and Out of the Body, and About Its Anticancer Activity in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)

Bayer

Phase 1 Active not recruiting
232 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡